Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer
Aim Apatinib is an effective treatment for patients with gynecological cancers. This study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum‐resistant ovarian cancer (PROC). Methods Totally, 105 patients with recurrent PROC receiving a...
Gespeichert in:
| Veröffentlicht in: | The journal of obstetrics and gynaecology research 2023-06, Vol.49 (6), p.1611-1619 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1619 |
|---|---|
| container_issue | 6 |
| container_start_page | 1611 |
| container_title | The journal of obstetrics and gynaecology research |
| container_volume | 49 |
| creator | Yang, Hailei Geng, Aizhi Wang, Zhenfeng Wu, Chuanzhong |
| description | Aim
Apatinib is an effective treatment for patients with gynecological cancers. This study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum‐resistant ovarian cancer (PROC).
Methods
Totally, 105 patients with recurrent PROC receiving apatinib plus chemotherapy (N = 51) and chemotherapy alone (N = 54) were retrospectively enrolled in this cohort study.
Results
Objective response rate (37.3% vs. 14.8%) (p = 0.009) and disease control rate (80.4% vs. 61.1%) (p = 0.030) were increased in the apatinib plus chemotherapy group versus the chemotherapy group. The median (95% confidence interval [CI]) progression‐free survival (PFS) and overall survival (OS) were 5.5 (3.4–7.6) and 21.4 (16.2–26.6) months in the apatinib plus chemotherapy group, and they were 3.8 (3.0–4.6) and 14.8 (11.9–17.7) months in the chemotherapy group. Meanwhile, the Kaplan–Meier curves revealed that PFS (p = 0.008) and OS (p = 0.012) were prolonged in the apatinib plus chemotherapy group versus the chemotherapy group. This finding was confirmed by multivariate Cox's proportional regression analyses: enter method (hazard ratio [HR] = 0.515, p = 0.007 for PFS; HR = 0.222, p 0.05). Grades 3 and 4 adverse events were neutropenia, hypertension, leukopenia, hand–foot syndrome, nausea and vomiting, fatigue, thrombocytopenia, and anemia in the apatinib plus chemotherapy group.
Conclusion
Apatinib combined with chemotherapy is a superior choice over chemotherapy alone for recurrent PROC management. |
| doi_str_mv | 10.1111/jog.15644 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2792502459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2792502459</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3774-7159e3b6b1ee975ab34f741746c37a951ea4bf2f9e45d8db61362d58d29cbe0f3</originalsourceid><addsrcrecordid>eNqNkUFu1TAQhi0EoqWw4ALIEpuySBs7ThwvUVUKqFI3sI7Gzrj1U2IHO2mbHUfgVtyDk-BHCgskJLwZ2_PNPzP6CXnJyhOWz-kuXJ-wuhHiETlkQsiilHXzON8rwYq2lM0BeZbSriyZVKx9Sg6qRrUtq9Uh-X5urTNgVgq-pwkszisNlsIEs_NOUxNG7Tz29M7NN3RwU0hhhIH24T7ERTvjPA2RTmAGN8M9DvQWY1rSf6Fj8GG-wQjTSnNy3xP9nLZeEc0SY37TadgPs4w_vn6LmFyaIX-GW4gOPDXgDcbn5ImFIeGLh3hEPr87_3T2vri8uvhw9vayMJWUopB5aax0oxmikjXoSlgpmBRNzoOqGYLQlluFou7bXjesanhftz1XRmNpqyNyvOlOMXxZMM3d6JLBYQCPYUkdl4rXJRe1yujrv9BdWKLP03W85UwoLkWZqTcbZWJIKaLtpuhGiGvHym7vbq667n65m9lXD4qLHrH_Q_62MwOnG3DnBlz_rdR9vLrYJH8CtV-2GA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2821492740</pqid></control><display><type>article</type><title>Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Yang, Hailei ; Geng, Aizhi ; Wang, Zhenfeng ; Wu, Chuanzhong</creator><creatorcontrib>Yang, Hailei ; Geng, Aizhi ; Wang, Zhenfeng ; Wu, Chuanzhong</creatorcontrib><description>Aim
Apatinib is an effective treatment for patients with gynecological cancers. This study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum‐resistant ovarian cancer (PROC).
Methods
Totally, 105 patients with recurrent PROC receiving apatinib plus chemotherapy (N = 51) and chemotherapy alone (N = 54) were retrospectively enrolled in this cohort study.
Results
Objective response rate (37.3% vs. 14.8%) (p = 0.009) and disease control rate (80.4% vs. 61.1%) (p = 0.030) were increased in the apatinib plus chemotherapy group versus the chemotherapy group. The median (95% confidence interval [CI]) progression‐free survival (PFS) and overall survival (OS) were 5.5 (3.4–7.6) and 21.4 (16.2–26.6) months in the apatinib plus chemotherapy group, and they were 3.8 (3.0–4.6) and 14.8 (11.9–17.7) months in the chemotherapy group. Meanwhile, the Kaplan–Meier curves revealed that PFS (p = 0.008) and OS (p = 0.012) were prolonged in the apatinib plus chemotherapy group versus the chemotherapy group. This finding was confirmed by multivariate Cox's proportional regression analyses: enter method (hazard ratio [HR] = 0.515, p = 0.007 for PFS; HR = 0.222, p < 0.001 for OS) and step‐forward method (HR = 0.608, p = 0.019 for PFS; HR = 0.346, p = 0.001 for OS). Additionally, the incidence of hypertension was increased in the apatinib plus chemotherapy group versus the chemotherapy group (p = 0.038), while others were not different between the two groups (all p > 0.05). Grades 3 and 4 adverse events were neutropenia, hypertension, leukopenia, hand–foot syndrome, nausea and vomiting, fatigue, thrombocytopenia, and anemia in the apatinib plus chemotherapy group.
Conclusion
Apatinib combined with chemotherapy is a superior choice over chemotherapy alone for recurrent PROC management.</description><identifier>ISSN: 1341-8076</identifier><identifier>EISSN: 1447-0756</identifier><identifier>DOI: 10.1111/jog.15644</identifier><identifier>PMID: 36988159</identifier><language>eng</language><publisher>Kyoto, Japan: John Wiley & Sons Australia, Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects ; apatinib ; Carcinoma, Ovarian Epithelial - drug therapy ; Chemotherapy ; Cohort Studies ; Disease control ; Doxorubicin ; Doxorubicin - adverse effects ; Female ; Humans ; Hypertension ; Leukopenia ; Neoplasm Recurrence, Local - therapy ; Neutropenia ; Ovarian cancer ; Ovarian Neoplasms ; Paclitaxel ; Paclitaxel - adverse effects ; Platinum ; recurrent platinum‐resistant ovarian cancer ; Retrospective Studies ; safety ; Survival ; Thrombocytopenia ; treatment response ; Vomiting</subject><ispartof>The journal of obstetrics and gynaecology research, 2023-06, Vol.49 (6), p.1611-1619</ispartof><rights>2023 Japan Society of Obstetrics and Gynecology.</rights><rights>2023 Japan Society of Obstetrics and Gynecology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3774-7159e3b6b1ee975ab34f741746c37a951ea4bf2f9e45d8db61362d58d29cbe0f3</citedby><cites>FETCH-LOGICAL-c3774-7159e3b6b1ee975ab34f741746c37a951ea4bf2f9e45d8db61362d58d29cbe0f3</cites><orcidid>0000-0002-9851-5410</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjog.15644$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjog.15644$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36988159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Hailei</creatorcontrib><creatorcontrib>Geng, Aizhi</creatorcontrib><creatorcontrib>Wang, Zhenfeng</creatorcontrib><creatorcontrib>Wu, Chuanzhong</creatorcontrib><title>Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer</title><title>The journal of obstetrics and gynaecology research</title><addtitle>J Obstet Gynaecol Res</addtitle><description>Aim
Apatinib is an effective treatment for patients with gynecological cancers. This study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum‐resistant ovarian cancer (PROC).
Methods
Totally, 105 patients with recurrent PROC receiving apatinib plus chemotherapy (N = 51) and chemotherapy alone (N = 54) were retrospectively enrolled in this cohort study.
Results
Objective response rate (37.3% vs. 14.8%) (p = 0.009) and disease control rate (80.4% vs. 61.1%) (p = 0.030) were increased in the apatinib plus chemotherapy group versus the chemotherapy group. The median (95% confidence interval [CI]) progression‐free survival (PFS) and overall survival (OS) were 5.5 (3.4–7.6) and 21.4 (16.2–26.6) months in the apatinib plus chemotherapy group, and they were 3.8 (3.0–4.6) and 14.8 (11.9–17.7) months in the chemotherapy group. Meanwhile, the Kaplan–Meier curves revealed that PFS (p = 0.008) and OS (p = 0.012) were prolonged in the apatinib plus chemotherapy group versus the chemotherapy group. This finding was confirmed by multivariate Cox's proportional regression analyses: enter method (hazard ratio [HR] = 0.515, p = 0.007 for PFS; HR = 0.222, p < 0.001 for OS) and step‐forward method (HR = 0.608, p = 0.019 for PFS; HR = 0.346, p = 0.001 for OS). Additionally, the incidence of hypertension was increased in the apatinib plus chemotherapy group versus the chemotherapy group (p = 0.038), while others were not different between the two groups (all p > 0.05). Grades 3 and 4 adverse events were neutropenia, hypertension, leukopenia, hand–foot syndrome, nausea and vomiting, fatigue, thrombocytopenia, and anemia in the apatinib plus chemotherapy group.
Conclusion
Apatinib combined with chemotherapy is a superior choice over chemotherapy alone for recurrent PROC management.</description><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>apatinib</subject><subject>Carcinoma, Ovarian Epithelial - drug therapy</subject><subject>Chemotherapy</subject><subject>Cohort Studies</subject><subject>Disease control</subject><subject>Doxorubicin</subject><subject>Doxorubicin - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Leukopenia</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Neutropenia</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms</subject><subject>Paclitaxel</subject><subject>Paclitaxel - adverse effects</subject><subject>Platinum</subject><subject>recurrent platinum‐resistant ovarian cancer</subject><subject>Retrospective Studies</subject><subject>safety</subject><subject>Survival</subject><subject>Thrombocytopenia</subject><subject>treatment response</subject><subject>Vomiting</subject><issn>1341-8076</issn><issn>1447-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFu1TAQhi0EoqWw4ALIEpuySBs7ThwvUVUKqFI3sI7Gzrj1U2IHO2mbHUfgVtyDk-BHCgskJLwZ2_PNPzP6CXnJyhOWz-kuXJ-wuhHiETlkQsiilHXzON8rwYq2lM0BeZbSriyZVKx9Sg6qRrUtq9Uh-X5urTNgVgq-pwkszisNlsIEs_NOUxNG7Tz29M7NN3RwU0hhhIH24T7ERTvjPA2RTmAGN8M9DvQWY1rSf6Fj8GG-wQjTSnNy3xP9nLZeEc0SY37TadgPs4w_vn6LmFyaIX-GW4gOPDXgDcbn5ImFIeGLh3hEPr87_3T2vri8uvhw9vayMJWUopB5aax0oxmikjXoSlgpmBRNzoOqGYLQlluFou7bXjesanhftz1XRmNpqyNyvOlOMXxZMM3d6JLBYQCPYUkdl4rXJRe1yujrv9BdWKLP03W85UwoLkWZqTcbZWJIKaLtpuhGiGvHym7vbq667n65m9lXD4qLHrH_Q_62MwOnG3DnBlz_rdR9vLrYJH8CtV-2GA</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Yang, Hailei</creator><creator>Geng, Aizhi</creator><creator>Wang, Zhenfeng</creator><creator>Wu, Chuanzhong</creator><general>John Wiley & Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9851-5410</orcidid></search><sort><creationdate>202306</creationdate><title>Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer</title><author>Yang, Hailei ; Geng, Aizhi ; Wang, Zhenfeng ; Wu, Chuanzhong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3774-7159e3b6b1ee975ab34f741746c37a951ea4bf2f9e45d8db61362d58d29cbe0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>apatinib</topic><topic>Carcinoma, Ovarian Epithelial - drug therapy</topic><topic>Chemotherapy</topic><topic>Cohort Studies</topic><topic>Disease control</topic><topic>Doxorubicin</topic><topic>Doxorubicin - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Leukopenia</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Neutropenia</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms</topic><topic>Paclitaxel</topic><topic>Paclitaxel - adverse effects</topic><topic>Platinum</topic><topic>recurrent platinum‐resistant ovarian cancer</topic><topic>Retrospective Studies</topic><topic>safety</topic><topic>Survival</topic><topic>Thrombocytopenia</topic><topic>treatment response</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Hailei</creatorcontrib><creatorcontrib>Geng, Aizhi</creatorcontrib><creatorcontrib>Wang, Zhenfeng</creatorcontrib><creatorcontrib>Wu, Chuanzhong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of obstetrics and gynaecology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Hailei</au><au>Geng, Aizhi</au><au>Wang, Zhenfeng</au><au>Wu, Chuanzhong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer</atitle><jtitle>The journal of obstetrics and gynaecology research</jtitle><addtitle>J Obstet Gynaecol Res</addtitle><date>2023-06</date><risdate>2023</risdate><volume>49</volume><issue>6</issue><spage>1611</spage><epage>1619</epage><pages>1611-1619</pages><issn>1341-8076</issn><eissn>1447-0756</eissn><abstract>Aim
Apatinib is an effective treatment for patients with gynecological cancers. This study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum‐resistant ovarian cancer (PROC).
Methods
Totally, 105 patients with recurrent PROC receiving apatinib plus chemotherapy (N = 51) and chemotherapy alone (N = 54) were retrospectively enrolled in this cohort study.
Results
Objective response rate (37.3% vs. 14.8%) (p = 0.009) and disease control rate (80.4% vs. 61.1%) (p = 0.030) were increased in the apatinib plus chemotherapy group versus the chemotherapy group. The median (95% confidence interval [CI]) progression‐free survival (PFS) and overall survival (OS) were 5.5 (3.4–7.6) and 21.4 (16.2–26.6) months in the apatinib plus chemotherapy group, and they were 3.8 (3.0–4.6) and 14.8 (11.9–17.7) months in the chemotherapy group. Meanwhile, the Kaplan–Meier curves revealed that PFS (p = 0.008) and OS (p = 0.012) were prolonged in the apatinib plus chemotherapy group versus the chemotherapy group. This finding was confirmed by multivariate Cox's proportional regression analyses: enter method (hazard ratio [HR] = 0.515, p = 0.007 for PFS; HR = 0.222, p < 0.001 for OS) and step‐forward method (HR = 0.608, p = 0.019 for PFS; HR = 0.346, p = 0.001 for OS). Additionally, the incidence of hypertension was increased in the apatinib plus chemotherapy group versus the chemotherapy group (p = 0.038), while others were not different between the two groups (all p > 0.05). Grades 3 and 4 adverse events were neutropenia, hypertension, leukopenia, hand–foot syndrome, nausea and vomiting, fatigue, thrombocytopenia, and anemia in the apatinib plus chemotherapy group.
Conclusion
Apatinib combined with chemotherapy is a superior choice over chemotherapy alone for recurrent PROC management.</abstract><cop>Kyoto, Japan</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>36988159</pmid><doi>10.1111/jog.15644</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9851-5410</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-8076 |
| ispartof | The journal of obstetrics and gynaecology research, 2023-06, Vol.49 (6), p.1611-1619 |
| issn | 1341-8076 1447-0756 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2792502459 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - adverse effects apatinib Carcinoma, Ovarian Epithelial - drug therapy Chemotherapy Cohort Studies Disease control Doxorubicin Doxorubicin - adverse effects Female Humans Hypertension Leukopenia Neoplasm Recurrence, Local - therapy Neutropenia Ovarian cancer Ovarian Neoplasms Paclitaxel Paclitaxel - adverse effects Platinum recurrent platinum‐resistant ovarian cancer Retrospective Studies safety Survival Thrombocytopenia treatment response Vomiting |
| title | Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A08%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20apatinib%20combined%20with%20liposomal%20doxorubicin%20or%20paclitaxel%20versus%20liposomal%20doxorubicin%20or%20paclitaxel%20monotherapy%20in%20patients%20with%20recurrent%20platinum%E2%80%90resistant%20ovarian%20cancer&rft.jtitle=The%20journal%20of%20obstetrics%20and%20gynaecology%20research&rft.au=Yang,%20Hailei&rft.date=2023-06&rft.volume=49&rft.issue=6&rft.spage=1611&rft.epage=1619&rft.pages=1611-1619&rft.issn=1341-8076&rft.eissn=1447-0756&rft_id=info:doi/10.1111/jog.15644&rft_dat=%3Cproquest_cross%3E2792502459%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2821492740&rft_id=info:pmid/36988159&rfr_iscdi=true |